|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib.|
|Rapid review commissioned||03/01/2017|
|Rapid review completed||27/02/2017|
|Rapid review outcome||Full pharmacoeconomic evaluation recommended at the submitted price.|
The HSE has approved reimbursement following confidential price negotiations October 2017.